Low-Dose Trimethoprim-Sulfamethoxazole Prophylaxis for Pneumocystis jirovecii Pneumonia in a Critically Ill Patient with HIV/TB Coinfection: Pharmacokinetics and Clinical Outcomes
Abstract
BACKGROUND: Pneumocystis jirovecii pneumonia (PJP) is a life-threatening opportunistic infection disease in immunocompromised patients, particularly those with advanced HIV and tuberculosis (TB) co-infection. Trimethoprim-sulfamethoxazole (TMP-SMZ) is recommended for PJP prophylaxis, but its pharmacokinetics (PK) and clinical efficacy in critically ill patients receiving multi-drug therapies (anti-TB, antiretroviral, and antifungals) remain poorly characterized.
CASE PRESENTATION: This study reported the PK profile, multi-drug management strategies and clinical outcomes of low-dose TMP-SMZ (a combined dose of 480 mg once daily, 50% of the standard prophylactic dose) for PJP prophylaxis in a critically ill patient with disseminated TB, advanced HIV (CD4+ count: 21 cells/μL), and concurrent infections. The patient received TMP-SMZ alongside anti-TB therapy (isoniazid, rifabutin, levofloxacin, linezolid), voriconazole, and antiretroviral therapy. Therapeutic drug monitoring (TDM) showed peak concentrations of sulfamethoxazole (SMZ) and trimethoprim (TMP) were 18.58 µg/mL and 0.48 µg/mL, with trough concentrations of 1.75 µg/mL and 0.03 µg/mL, respectively. No drug-drug interactions were observed with concurrent voriconazole. The patient achieved stable recovery and without PJP or TMP-SMZ-related adverse events occurred during treatment and 6-month follow-up.
CONCLUSION: This case reported the feasibility of low-dose TMP-SMZ for PJP prevention in high-risk, critically ill…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.